Development
Vera Therapeutics, Inc.
VERA
$20.64
$0.190.93%
NASDAQ
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.45% | -6.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.97% | -29.71% | |||
| Operating Income | 0.97% | 29.71% | |||
| Income Before Tax | 0.29% | 32.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.29% | 32.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.29% | 32.95% | |||
| EBIT | 0.97% | 29.71% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 0.48% | 42.95% | |||
| Normalized Basic EPS | 0.46% | 43.01% | |||
| EPS Diluted | 0.48% | 42.95% | |||
| Normalized Diluted EPS | 0.46% | 43.01% | |||
| Average Basic Shares Outstanding | 0.21% | 17.53% | |||
| Average Diluted Shares Outstanding | 0.21% | 17.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||